This case report examines three patients with relapsed/refractory FLT3-ITD + acute myeloid leukemia (AML) treated with FLT3 inhibitors (FLT3i) and venetoclax (VEN). While the combination therapy showed promising antileukemic activity, all patients experienced severe myelosuppression, leading to treatment interruptions. Two patients died following disease progression after therapy discontinuation, while one maintained remission with an alternating treatment schedule. These cases highlight the importance of minimizing treatment interruptions while balancing infection risks and suggest that combination or sequential therapy with VEN and FLT3i may be effective for relapsed/refractory (R/R) FLT3-ITD + AML when treatment duration and dosing are properly managed.
Ikeda et al. (Wed,) studied this question.